Medications

A new drug target for liver cancer

National University of Singapore researchers have discovered that the MOAP-1 protein plays a role in reducing liver cancer risk by suppressing the hyper-active cancer-promoting Nrf2 cellular signaling pathway.

Oncology & Cancer

Armoring anti-cancer T cells against immunosuppressants

Duke-NUS Medical School researchers, together with collaborators in Singapore, have designed armored immune cells that can attack recurring cancer in liver transplant patients, while temporarily evading immunosuppressant ...

Oncology & Cancer

Chemotherapy drug more effective when combined with microbubbles

Hepatocellular carcinoma is a particularly stubborn form of cancer with few treatments and a high mortality rate. It is usually treated by blocking the flow of blood to the tumor to induce cancer cell death. The common treatment, ...

Oncology & Cancer

Liver cancer: Awareness of hepatitis D must be raised

Of all the hepatitis viruses, D is the most poorly known. This small virus, which can only infect people already infected with Hepatitis B, has so far been little studied. Hepatitis D is one of the most dangerous forms ...

Gastroenterology

From obesity to liver cancer: Preventing the worst

By identifying the role of a specific protein in the development of obesity-related liver diseases, UNIGE researchers pave the way for better diagnosis, and potentially better treatment.

Diseases, Conditions, Syndromes

Patients with cirrhosis have considerable financial burden

(HealthDay)—The considerable financial burden of cirrhosis medical care is associated with lower surveillance for hepatocellular carcinoma (HCC), according to a study presented at The Liver Meeting, the annual meeting of ...

page 1 from 13